Evercore ISI Group Maintains In-Line on Teladoc Health, Raises Price Target to $9
Portfolio Pulse from Benzinga Newsdesk
Evercore ISI Group analyst Elizabeth Anderson maintains an In-Line rating on Teladoc Health and raises the price target from $8 to $9.
October 08, 2024 | 5:19 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Evercore ISI Group has maintained an In-Line rating for Teladoc Health and increased the price target from $8 to $9, indicating a slightly positive outlook.
The increase in price target from $8 to $9 by Evercore ISI Group suggests a slightly positive outlook for Teladoc Health. The maintained In-Line rating indicates that the stock is expected to perform in line with the market. This could lead to a modest positive impact on the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100